Уноси

HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations (2017-10)

A. Uzunović, S. Pilipović, B. Tubić, A. Sapčanin, I. Tahirović, HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations, Acta Pharmaceutica Hungarica – 7th BBBB Edition, pp. 3 - 4, Oct, 2017
Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom (2018-10)

B. Tubić, B. Marković, S. Vladimirov, V. Dobričić, J. Poljarević, A. Savić, T. Sabo, Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom, Arhiv za farmaciju 2018;68, pp. 106 - 107, Oct, 2018
Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja (2018-10)

V. Dobričić, J. Savić, B. Tubić, K. Nikolić, J. Brborić, B. Marković, O. Čudina, Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja, Arhiv za farmaciju 2018;68, pp. 112 - 113, Oct, 2018
Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2018-10)

B. Tubić, J. Aničić, T. Spasojević, A. Cvijanović, A. Zolak, Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini, Arhiv za farmaciju 2018;68, pp. 277 - 278, Oct, 2018
Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest (2018-11)

B. Tubić, Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest, Signals of Current Interest, pp. 25 - 25, Nov, 2018
Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi (2018-11)

B. Tubić, Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi, Zbornik radova, pp. 15 - 19, Nov, 2018
Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2019-04)

J. Aničić, A. Zolak, B. Tubić, T. Spasojević, A. Cvijanović, Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini, Knjiga sažetaka, 2019, pp. 177 - 177, Apr, 2019
Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini (2019-04)

T. Spasojević, B. Tubić, A. Cvijanović, A. Zolak, Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini, Knjiga sažetaka, 2019, pp. 245 - 245, Apr, 2019
Discovery of membrane permeability, pharmacokinetics properties and mechanism of action for analogs of ethylenediamine-N,N’-di-2-(3-cyclohexyl)propionic acid and 1,3-propandiamine-N,N’-di-2-(3-cyclohexyl)propionic acid with antiproliferative activity using in vitro and in silico methods (2019-05)

B. Tubić, B. Marković, T. Sabo, Discovery of membrane permeability, pharmacokinetics properties and mechanism of action for analogs of ethylenediamine-N,N’-di-2-(3-cyclohexyl)propionic acid and 1,3-propandiamine-N,N’-di-2-(3-cyclohexyl)propionic acid with antiproliferative activity using in vitro and in silico methods, CMBEBIH 2019, Springer, Proceedings of the International Conference on Medical and Biological Engineering, 16–18 May 2019 Banja Luka, Bosnia and Herzegovina, pp. 357 - 369, May, 2019
Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina (2019-09)

B. Tubić, S. Kecman, R. Škrbić, L. Nježić, N. Stojaković, S. Goločorbin Kon, M. Mikov, Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina, ABSTRACT BOOK, pp. 95 - 96, Sep, 2019
DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS (2019-09)

S. Kecman, B. Tubić, R. Škrbić, N. Stojaković, L. Nježić, S. Goločorbin Kon, M. Mikov, DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS, ABSTRACT BOOK, pp. 265 - 266, Sep, 2019
INHIBITORI EGFR U TERAPIJI NSCLC (2019-10)

B. Tubić, INHIBITORI EGFR U TERAPIJI NSCLC, Knjiga sažetaka, pp. 160 - 161, Oct, 2019
MOLEKULARNA POZADINA NAJČEŠĆIH NUSPOJAVA U BOSNI I HERCEGOVINI (2019-10)

M. Kondža, B. Tubić, A. Zolak, MOLEKULARNA POZADINA NAJČEŠĆIH NUSPOJAVA U BOSNI I HERCEGOVINI, Knjiga sažetaka, pp. 306 - 307, Oct, 2019
Cardiovascular toxicity of antineoplastic medicines in Bosnia and Herzegovina (2020)

B. Tubić, Cardiovascular toxicity of antineoplastic medicines in Bosnia and Herzegovina, Macedonian PharmaOnline ISSN 1857 - 8969, pp. 19 - 20, 2020
Antioxidant activity of Lamiaceae teas prepared in household (2023)

Ж. Гагић, N. Mandić-Kovačević, Б. Тубић, Antioxidant activity of Lamiaceae teas prepared in household, 2023
ESMO Водич за дијагностику, лијечење и праћење малигног тумора бубрега (2016)

С. Јунгић, J. Berendika, Р. Гајанин, З. Гојковић, С. Марић, S. Milićević, А. Салапура, M. Štrbac, Б. Тубић, M. Vještica, М. Жигић, ESMO Водич за дијагностику, лијечење и праћење малигног тумора бубрега, Удружење онколога Републике Српске, 2016
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

B. Godman, M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. Abu Bakar, S. Abdur Rahim, N. Sultana, F. Deeba, H. Khan, M. Alam, I. Jahan, Z. Kamal, H. Hasan, M. E-Murshid, S. Nahar, M. Haque, S. Dutta, J. Pallavi Abhayanand, R. Jeet Kaur, G. Rwegerera, R. Nascimento, I. Godoi, M. Irfan, A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. Sefah, J. Acharya, S. Opanga, L. Njeri, D. Kimonge, H. Kwon, S. Bae, K. Khuan, A. Abu Bakar, I. Sani, T. Khan, S. Hussain, Z. Saleem, O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. Kalungia, I. Hoxha, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Furst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. Tagoa, R. Banzi, J. Wale, M. Jakovljevic, The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future, Frontiers in public health, Vol. 9, pp. 1 - 21, Jun, 2021
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications (2021-07)

Б. Тубић, V. Marković Peković, С. Јунгић, E. Allocati, B. Godman, Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications, Medicine access @ point of care, Vol. 5, pp. 1 - 7, Jul, 2021
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

A. Pisana, B. Wettermark, A. Kurdi, Б. Тубић, C. Pontes, C. Zara, E. Van Ganse, G. Petrova, I. Mardare, J. Furst, M. Roig-Izquierdo, O. Melien, P. Vella Bonanno, R. Banzi, V. Marković Peković, Z. Mitkova, B. Godman, Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries, Frontiers in Pharmacology, No. 873556, pp. 1 - 16, Jun, 2022

Уноси

HPLC determination of benzaldehyde in benzyl alcohol containing injectable formulations (2017-10)

Fizičko‐hemijska i ADME karakterizacija analoga estara etilendiamin‐N,N’‐di‐2‐(3‐cikloheksil)propanske kiseline sa potencijalnim citotoksičnim dejstvom (2018-10)

Primena PAMPA tehnike i QSPR analize u proceni gastrointestinalne apsorpcije i dizajniranju novih biološki aktivnih jedinjenja (2018-10)

Uticaj pravilnika kojim se regulišu maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2018-10)

Bosnia and Herzegovina take brave steps in pharmacovigilance, Signals of Current Interest (2018-11)

Sličnosti i razlike ciljane terapije u tretmanu malignih oboljenja – nibovi versus mabovi (2018-11)

Utjecaj Pravilnika kojim se reguliraju maksimalne veleprodajne cijene lijekova na cijene lijekova u Bosni i Hercegovini (2019-04)

Specifičnosti potrošnje antimikrobnih lijekova u Bosni i Hercegovini (2019-04)

Challenges in authorization and administration of biological drugs and biosimilars in Bosnia and Herzegovina (2019-09)

DRUG MARKET IN BOSNIA AND HERZEGOVINA – TO WHAT EXTENT THE PHARMACEUTICAL INDUSTRY IS IN LINE WITH THE POPULATION’S NEEDS (2019-09)

INHIBITORI EGFR U TERAPIJI NSCLC (2019-10)

MOLEKULARNA POZADINA NAJČEŠĆIH NUSPOJAVA U BOSNI I HERCEGOVINI (2019-10)

Cardiovascular toxicity of antineoplastic medicines in Bosnia and Herzegovina (2020)

Antioxidant activity of Lamiaceae teas prepared in household (2023)

ESMO Водич за дијагностику, лијечење и праћење малигног тумора бубрега (2016)

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications (2021-07)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)